SCHEMBL5535481

SCHEMBL5535481

CCNC1CCN(c2cc[c]cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
NMT1 P30419 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
AKT1 P31749 1/20 0.36
NPY2R P49146 1/20 0.36
GAA P10253 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 1/20 0.35
RAD52 P43351 1/20 0.35
GFER P55789 1/20 0.35
ME3 Q16798 1/20 0.35
VCP P55072 1/20 0.34
CDK4 P11802 1/20 0.34
CDK6 Q00534 1/20 0.34
L3MBTL3 Q96JM7 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DPP4 P27487 1/20 0.34
CHRNA7 P36544 1/20 0.33
CARM1 Q86X55 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537860 0.87 VCP (0.40) SMN1; SMN2NPY2RKDM4EVCPCDK4
SCHEMBL13798544 0.84 CHRNA7 (0.50) HSP90AA1HSP90AB1SMN1; SMN2NPY2RME3
SCHEMBL5543412 0.84 VCP (0.49) VCPDPP4CARM1PRMT6PRMT8
SCHEMBL5540040 0.83 VCP (0.46) GAAKDM4EVCP
SCHEMBL8725147 0.83 ADRB1 (0.46) HSP90AA1HSP90AB1SMN1; SMN2AKT1GAA
SCHEMBL13380458 0.83 MAPT (0.54) HSP90AA1HSP90AB1SMN1; SMN2AKT1NPY2R
SCHEMBL5538029 0.82 GNAI3 (0.45) GAAKDM4EVCP
SCHEMBL5537556 0.81 ME3 (0.52) HSP90AA1HSP90AB1SMN1; SMN2NPY2RGAA
SCHEMBL803329 0.81 ITGB3 (0.49) HSP90AA1HSP90AB1AKT1VCPCDK4
SCHEMBL22837858 0.81 HSP90AA1 (0.40) HSP90AA1HSP90AB1NMT1SMN1; SMN2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSP90AA1 2426/4885HSP90AB1 2045/4885NMT1 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.